Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV568 in moderate to severe COPD
NCT01867762Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of RV568 in chronic obstructive pulmonary disease (COPD), sponsored by Janssen Pharmaceutical. Started Sep 2013; status: completed.
02
Drugs
RV568
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01867762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01867762.